Novartis loses appeal over patent for heart drug Entresto
Intellectual Property 2025-03-24 11:50 pm
Pharmacor will be allowed to sell a generic version of heart drug Entresto after the Full Court rejected Swiss drug giant Novartis’ appeal of a ruling that found an extension of the term of its patent for the drug was invalidly granted.
For information on rights and reprints, contact subscriptions@lawyerly.com.au